PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1663438
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1663438
AI-based Digital Pathology Market size was valued at US$ 85.6 Million in 2024, expanding at a CAGR of 15.80% from 2025 to 2032.
AI-based digital pathology is a cutting-edge method of using digital technologies and artificial intelligence to diagnose and analyze illnesses. In order to identify patterns, anomalies, and particular disease signs, pathology slides are digitized into high-resolution images and subsequently sent to AI algorithms for analysis. By automating repetitive procedures, increasing diagnostic precision, and spotting minute details that would be overlooked during manual inspection, these AI systems might help pathologists. The AI-based digital pathology market is growing as a result of the growing emphasis on hospital cost control and efficiency enhancement, the rising need for technologically sophisticated solutions, and the rising number of incorrect diagnoses. Additionally, it is anticipated that government-funded research initiatives that support the creation of cutting-edge digital tools for pathology would support the AI-based digital pathology market growth.
AI-based Digital Pathology Market- Market Dynamics
Growing demand for personalized medication
The market for AI-based digital pathology is anticipated to increase in the future due to the growing demand for personalized medication. Customizing medical care and treatment to each patient's unique needs, preferences, and traits is known as personalized medicine. Personalized medicine is becoming more and more necessary in order to improve efficacy and decrease side effects by customizing therapies to each patient's unique genetic profile, lifestyle choices, and illness features. By making it possible to analyze genetic data and medical images more accurately and efficiently, AI-based digital pathology supports personalized medicine by facilitating more precise diagnosis, improved identification of disease subtypes, and customized treatment regimens that fit each patient's particular biological profile. For instance, a report released in February 2023 by the US-based professional membership organization Personalized Medicine Coalition stated that the approval of 12 new personalized medications in 2022-roughly 34% of all new therapies-represented a notable increase over prior years. Thus, the market for AI-based digital pathology is expanding due to the growing demand for tailored therapy.
AI-based Digital Pathology Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.80% over the forecast period (2025-2032)
Based on neural network segmentation, the convolutional neural networks (CNNs) were predicted to show maximum market share in the year 2024
Based on application segmentation, drug discovery was the leading segment in 2024
Based on end use segmentation, hospitals & reference laboratories were the leading segment in 2024
On the basis of region, Asia-Pacific was the leading revenue generator in 2024
The Global AI-based Digital Pathology Market is segmented on the basis of Neural Network, Component, Application, End Use, and Region.
On the basis of component, the market is segregated into Scanners and Software. In 2024, the market was dominated by the software category due to the increasing use of artificial intelligence software in digital pathology, which has been fueled by a decrease in pathologists' time, accuracy, and speed of results, enabling physicians to assess a patient's health and schedule recovery medication rapidly. Additionally, AI may be used effectively to store patient health data and retrieve results, which will increase the demand for AI-based digital pathology software during the study period.
Based on end use, the market is divided into Hospitals & Reference Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. In 2024, the hospitals & reference laboratories category held a dominant market share. Hospitals and reference labs will probably deal with an increasing number of pathology-related cases every day. The increasing burden for pathology jobs will need the use of AI due to its ability to produce reliable results and its time-saving capabilities. Additionally, hospitals can reduce the number of pathologists they require to manage more cases thanks to AI. This will further open up new avenues for the global AI-based digital pathology market to grow in the years to come.
AI-based Digital Pathology Market- Geographical Insights
In 2024, Asia-Pacific held a dominant position in the global market for AI-based Digital Pathology. The market for AI-based digital pathology is expanding due to the expanding application of AI in healthcare sectors in developing nations like China and India. By 2025, the healthcare AI market in India is anticipated to expand at a 40% CAGR, according to NASSCOM. This illustrates the growing usage of AI in the medical field, which could encourage its application in pathology due to its speedy completion of repetitive tasks and capacity to save pathologists time. Because artificial intelligence can do some pathologist-related duties, the presence of lower-level pathologists in the area is pushing healthcare practitioners to use it, increasing demand for it during the research period.
However, throughout the projected period, the North America region is anticipated to see the fastest CAGR because of the growing use of telemedicine. Due to strict lockdown requirements, COVID-19 encouraged the use of telemedicine instead of in-person sessions. Medicare beneficiaries in the US have been using telemedicine more frequently since the epidemic, according to the US Department of Health and Human Services. In the United States, there were 989 million in-person medical visits in 2020, up from 1.1 billion in 2019. By 2020, there were almost 52.7 million telemedicine appointments, up from 8,40,000 in 2019. AI-based technologies that assist physicians in treating patients remotely will be required as this trend, which is anticipated to increase due to decreased transaction costs, develops.
Leading players in the AI-based digital pathology market, such as DoMore Diagnostics AS, Aiforia Technologies, Aiosyn, Deep Bio, F. Hoffmann-La Roche, and others, are concentrating on creating cutting-edge products, such as sophisticated cancer detection instruments to boost patient outcomes, expedite processes, and increase diagnostic precision. AI-powered advanced cancer detection tools use deep learning models and machine learning algorithms to evaluate pathology slides and medical images, improving the precision of tumour identification and classification. For instance, in February 2022, Crosscope Inc. and MindPeak GmbH partnered to include MindPeak's image analysis tools into Crosscope's Digital Pathology platform. Crosscope's AI capabilities are improved by this collaboration, allowing them to offer complete digital pathology solutions. Through the smooth integration of cutting-edge AI tools, the collaboration seeks to streamline Histopathology workflows, assisting pathologists in enhancing lab productivity and providing prompt and significant diagnoses for ER, PR, and Ki-67 IHC analysis. Treatment outcomes for patients are expected to improve as a result of the integration.
Recent Development
January 2024: Roche declared that it had finalized a merger deal to buy Berkeley, California-based Carmot Therapeutics, Inc. ("Carmot"), a privately held US business. Carmot's research and development portfolio includes a range of preclinical studies and clinically staged oral and subcutaneous incretins with best-in-class potential to treat obesity in individuals with and without diabetes.
October 2023: With the help of cloud service provider Amazon Web Services, Inc., F. Hoffmann-La Roche Ltd. and Ibex Medical Analytics Ltd. have partnered to offer AI-powered cancer detection solutions. Through the Navify Digital Pathology software platform, this partnership seeks to provide pathology labs with access to Ibex's AI-driven decision support capabilities. Clinicians can get help diagnosing prostate and breast cancer through this integration.
September 2023: In the European, Canadian, and Asia Pacific markets, Hologic, Inc. and Bayer AG have teamed together to offer contrast-enhanced mammography (CEM) solutions for better breast cancer detection. By combining Bayer and Hologic's technology, the alliance hopes to make it easier to apply contrast media during mammography exams. The collaboration is centred on offering radiologists complete product bundles, practical instruction, and smooth CEM workflow integration.
June 2023: Proscia Inc., a U.S.-based supplier of digital and computational pathology solutions, has partnered with MindPeak GmbH. Through closely coordinated AI-powered workflows, this collaboration seeks to assist pathologists in reaching more effective, knowledgeable, and repeatable clinical conclusions. The objective is to increase cancer patients' access to better diagnostics.